Skip to content
In English |
En español
Search
Clinical Trials Search Results
Page Options
E-Mail This Search
Clinical Trial Questions?
Get Help:
1-800-4-CANCER
Quick Links
Help Using the NCI Clinical Trials Search Form
Educational Materials About Clinical Trials
About NCI's Cancer Clinical Trials Registry
Dictionary of Cancer Terms
NCI Drug Dictionary
View Content for:
Patients
Health Professionals
Display:
Title
Description with:
Locations
Eligibility
Full Trial Description
Custom
Results 1-7 of 7 for your search:
Drug:
c-Met inhibitor ARQ 197
Find trials that include:
Any drugs shown
Trial Status:
Active
Hide Search Criteria
Show Search Criteria
Help with Results
Select All on Page
Sort by:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Show
10
25
50
100
200
Results per Page
1.
Phase 2 Study in Patients With MiT Tumors
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
13 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
ARQ 197-204
, NCT00557609
2.
Trial of ARQ 197 in Patients With Unresectable Hepatocellular Carcinoma (HCC) Who Have Failed One Prior Systemic Therapy
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
ARQ 197-215
, NCT00988741
3.
ARQ 197 for Subjects With Relapsed or Refractory Germ Cell Tumors
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
16 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
ARQ 197-A-U251
, NCT01055067
4.
A Phase 1 Study of ARQ 197 in Patients With Solid Tumors
Phase:
Phase I
Type:
Treatment
Status:
Active
Age:
20 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
ARQ 197-0701
, NCT00609921
5.
Safety Study of ARQ 197 in Cirrhotic Patients With Hepatocellular Carcinoma (HCC)
Phase:
Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
ARQ 197-114
, NCT00802555
6.
Dose Escalation Study of ARQ 197 in Combination With Sorafenib in Adult Patients With Advanced Solid Tumors
Phase:
Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
ARQ 197-116
, NCT00827177
7.
Dose Escalation Study of ARQ 197 in Combination With Gemcitabine in Adult Patients With Advanced Solid Tumors
Phase:
Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
ARQ 197-117
, NCT00874042
Select All on Page
Help with Results
